Linaclotide (Linzess): Uses, Mechanism, and Side Effects

Chronic constipation and irritable bowel syndrome with constipation can be persistent and disruptive. Linaclotide is a prescription medicine developed specifically to address these conditions by working within the gut itself.

Key takeaways

• Linaclotide is approved under the brand name Linzess for constipation-related conditions in adults and certain pediatric patients.
• It works as a guanylate cyclase-C agonist, acting locally in the intestine rather than being absorbed systemically.
• The label carries a boxed warning.
• Across 62 registered trials, studies span early dose-finding work through long-term, real-world use assessments.
• FAERS reports most frequently mention diarrhoea, drug ineffectiveness, and off label use, alongside constipation and nausea.

What Linaclotide Is

Linaclotide belongs to a drug class called guanylate cyclase-C agonists. It is structurally related to natural human peptides called guanylin and uroguanylin. Linaclotide and its active metabolite bind to receptors on the surface of the intestinal lining. This activation raises levels of a molecule called cGMP inside and outside intestinal cells, which in turn stimulates the secretion of chloride and bicarbonate into the gut. The result is increased fluid in the intestine, intended to ease bowel movement.

What Linaclotide Is Approved For

Linaclotide, sold as Linzess, is approved for irritable bowel syndrome with constipation (IBS-C) in adults and in pediatric patients age 7 and older. It is also approved for chronic idiopathic constipation (CIC) in adults and for functional constipation in pediatric patients age 2 and older. The product label carries a boxed warning, which prescribers and patients should review carefully.

What the Evidence Shows

Linaclotide has been studied in 62 registered clinical trials. An early Phase 2 study evaluated a range of doses in patients with IBS-C and has been completed. A later Phase 4 open-label study assessed long-term immunogenicity in adults with IBS-C or chronic idiopathic constipation and has also been completed. A newer, currently recruiting trial is exploring linaclotide's use in preparation for colonoscopy.

Reported Side Effects

Data from the FDA Adverse Event Reporting System (FAERS) reflect counts of submitted reports, not confirmed rates of incidence or proof of a causal link. The most commonly reported terms for linaclotide are gastrointestinal in nature, led by diarrhoea (4,703 reports) and constipation (1,998), along with nausea (1,476), abdominal distension (1,170), and abdominal pain (1,063). Reports of drug ineffectiveness (4,516) and off label use (3,345) were also common, as was fatigue (1,171).